International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update

AP IJzerman, KA Jacobson, CE Müller… - Pharmacological …, 2022 - ASPET
Our previous International Union of Basic and Clinical Pharmacology report on the
nomenclature and classification of adenosine receptors (2011) contained a number of …

Radioprotection and radiomitigation: from the bench to clinical practice

E Obrador, R Salvador, JI Villaescusa, JM Soriano… - Biomedicines, 2020 - mdpi.com
The development of protective agents against harmful radiations has been a subject of
investigation for decades. However, effective (ideal) radioprotectors and radiomitigators …

Photocatalytic anti-Markovnikov hydroamination of alkenes with primary heteroaryl amines

EP Geunes, JM Meinhardt, EJ Wu… - Journal of the American …, 2023 - ACS Publications
We report a light-driven method for the intermolecular anti-Markovnikov hydroamination of
alkenes with primary heteroaryl amines. In this protocol, electron transfer between an amine …

Focusing on adenosine receptors as a potential targeted therapy in human diseases

WI Effendi, T Nagano, K Kobayashi, Y Nishimura - Cells, 2020 - mdpi.com
Adenosine is involved in a range of physiological and pathological effects through
membrane-bound receptors linked to G proteins. There are four subtypes of adenosine …

Cancer biology and molecular genetics of A3 adenosine receptor

C Mazziotta, JC Rotondo, C Lanzillotti, G Campione… - Oncogene, 2022 - nature.com
Abstract A3 adenosine receptor (A3AR) is a cell membrane protein, which has been found to
be overexpressed in a large number of cancer types. This receptor plays an important role in …

Glaucoma clinical research: Trends in treatment strategies and drug development

L Storgaard, TL Tran, JC Freiberg, AS Hauser… - Frontiers in …, 2021 - frontiersin.org
Purpose: To investigate the trends and progresses in glaucoma research by searching two
major clinical trial registries; clinicaltrials. gov, and Australianclinicaltrials. gov. au. Methods …

Purinergic signaling orchestrating neuron-glia communication

P Agostinho, D Madeira, L Dias, AP Simões… - Pharmacological …, 2020 - Elsevier
This review discusses the evidence supporting a role for ATP signaling (operated by P 2 X
and P 2 Y receptors) and adenosine signaling (mainly operated by A 1 and A 2A receptors) …

Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets

Y Zhao, W Xiong, C Li, R Zhao, H Lu, S Song… - … and Targeted Therapy, 2023 - nature.com
Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects
the survival of aerobic species and plays a prominent role in cardiovascular diseases. From …

Adenosine receptor antagonists: Recent advances and therapeutic perspective

A Saini, R Patel, S Gaba, G Singh, GD Gupta… - European Journal of …, 2022 - Elsevier
Adenosine is an endogenous purine-based nucleoside expressed nearly in all body tissues.
It regulates various body functions by activating four G-protein coupled receptors, A 1, A 2A …

Pharmacology of adenosine receptors: Recent advancements

F Vincenzi, S Pasquini, C Contri, M Cappello, M Nigro… - Biomolecules, 2023 - mdpi.com
Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still
underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues …